Vitamin D Endocrine System and the Immune Response in Rheumatic Diseases

Vitamins and Hormones

Volumn 86, Issue , 2011, Pages 327-351

  Cutolo, Maurizio ^a   Plebani, M ^b   Shoenfeld, Yehuda ^c,d   Adorini, Luciano ^e   Tincani, Angela ^f  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c SHEBA MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e INTERCEPT PHARMACEUTICALS   (United States)

^f UNIVERSITY OF BRESCIA   (Italy)

Author keywords

D hormone; Immune response; Psoriatic arthritis; Rheumatoid arthritis; Systemic lupus erythematosus; VDR agonists; Vitamin D; Vitamin D supplementation

Indexed keywords

ANTIRHEUMATIC AGENT; CALCITRIOL RECEPTOR; VITAMIN D;

ANIMAL; AUTOIMMUNE DISEASE; BOOK; DIET SUPPLEMENTATION; DRUG ANTAGONISM; ENDOCRINE DISEASE; ENDOCRINE SYSTEM; HUMAN; IMMUNITY; IMMUNOLOGY; IMMUNOMODULATION; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PSORIASIS; RHEUMATIC DISEASE;

ANIMALS; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; ENDOCRINE SYSTEM; ENDOCRINE SYSTEM DISEASES; HUMANS; IMMUNITY; IMMUNOMODULATION; PSORIASIS; RECEPTORS, CALCITRIOL; RHEUMATIC DISEASES; VITAMIN D;

EID: 79952691795     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386960-9.00014-9     Document Type: Book

References (88)

1. Abe J., et al. Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of vitamin D3: 22-oxa-1 alpha, 25-dihydroxyvitamin D3. J. Nutr. Sci. Vitaminol. (Tokyo) 1990, 36:21-31.
2. Adams J.S., Hewison M. Unexpected actions of vitamin D: New perspectives on the regulation of innate and adaptive immunity. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4:80-90.
3. Adorini L., Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 2008, 4:404-412.
4. Adorini L., Penna G., Giarratana N., Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J. Cell. Biochem. 2003, 88:227-233.
5. Aloia J.F., et al. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am. J. Clin. Nutr. 2008, 87:1952-1958.
6. Amital H., Szekanecz Z., Szücs G., Dankó K., Nagy E., Csépány T., Corocher N., Agmon-Levin N., Orbach H., Zandman-Goddard G., Shoenfeld Y. Serum concentrations of 25-OH Vitamin D in SLE patients are inversely related to disease activity-Is it time to routinely supplement SLE patients with vitamin D?. Ann. Rheum. Dis. 2010, 69:1155-1157.
7. Andjelkovic Z., Vojinovic J., Pejnovic N., Popovic M., Dujic A., Mitrovic D., et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 1999, 17:453-456.
8. Andjelkovic Z., Vojinovic J., Pejnovic N., et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 1999, 17:453-456.
9. Andjelkovic Z., et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 1999, 17:453-456.
10. Arnson Y., Amital H., Shoenfeld Y. Vitamin D and autoimmunity: New aetiological and therapeutic considerations. Ann. Rheum. Dis. 2007, 66:1137-1142.
11. Bertsias G., Ioannidis J.P., Boletis J., Bombardieri S., Cervera R., Dostal C., Font J., Gilboe I.M., Houssiau F., Huizinga T., Isenberg D., Kallenberg C.G., et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Theurapeutics. Ann. Rheum. Dis. 2008, 67:195-205.
12. Bettelli E., Korn T., Kuchroo V.K. Th17: The third member of the effector T cell trilogy. Curr. Opin. Immunol. 2007, 19:652-657.
13. Binkley N., Krueger D., Gemar D., Drezner M.K. Correlation among 25-hydroxy-vitamin D assays. J. Clin. Endocrinol. Metab. 2008, 93:1804-1808.
14. Borba V.Z.C., Vieira J.G.H., Kasamatsu T., Radominski S.C., Sato E.I., Lazaretti-Castro M. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos. Int. 2009, 20:427-433.
15. Braun-Moscovici Y., et al. Vitamin D level: Is it related to disease activity in inflammatory joint disease?. Ann Rheum Dis. 2009, 69(6):1155-1157.
16. Bultink I.E., Lems W.F., Kostense P.J., Dijkmans B.A., Voskuyl A.E. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005, 52(7):2044-2050.
17. Cantorna M.T., et al. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J. Nutr. 1998, 128:68-72.
18. Carter G.D., Jones J.C. Use of a common standard improves the performance of liquid chromatography-tandem mass spectrometry methods for serum 25-hydroxyvitamin D. Ann. Clin. Biochem. 2009, 46:79-81.
19. Carter G.D., Carter R., Jones J., Berry J. How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin. Chem. 2004, 50:2195-2197.
20. Carvalho J.F., Blank M., Kiss E., Tarr T., Amital H., Shoenfeld Y. Anti-vitamin D, vitamin D in SLE: Preliminary results. Ann. N. Y. Acad. Sci. 2007, 1109:550-557.
21. Cavalier E., Wallace M., Knox S., Mistretta V.I., Cormier C., Souberbielle J.C. Serum vitamin D measurement may not reflect what you give to your patients. J. Bone Miner. Res. 2008, 23:1864-1865.
22. Chen S., Sims G.P., Chen X.X., Gu Y.Y., Chen S., Lipsky P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 2007, 179:1634-1647.
23. Costenbader K.H., et al. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann. Rheum. Dis. 2008, 67:530-535.
24. Craig S.M., Yu F., Curtis J.R., Alarcón G.S., Conn D.L., Jonas B., Callahan L.F., Smith E.A., Moreland L.W., Bridges S.L., Mikuls T.R. Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis. J. Rheumatol. 2010, 37:275-281.
25. Cutolo M. Vitamin D and autoimmune rheumatic diseases. Rheumatology (Oxford) 2009, 48:210-212.
26. Cutolo M., Otsa K. Review: Vitamin D, immunity and lupus. Lupus 2008, 17:6-10.
27. Cutolo M., Otsa K., Laas K., Yprus M., Lehtme R., Secchi M.E., Sulli A., Paolino S., Seriolo B. Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin. Exp. Rheumatol. 2006, 24:702-704.
28. Cutolo M., Otsa K., Laas K., et al. Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin. Exp. Rheumatol. 2006, 24:702-704.
29. Cutolo M., Otsa K., Yprus M., et al. Vitamin D and rheumatoid arthritis: Comment on the letter by Nielen et al. Arthritis Rheum. 2007, 56:1719-1720.
30. Cutolo M., Otsa K., Paolino S., Yprus M., Veldi T., Seriolo B. Vitamin D involvement in rheumatoid arthritis and systemic lupus erythaematosus. Ann. Rheum. Dis. 2009, 68:446-447.
31. Damanhouri L.H. Vitamin D deficiency in Saudi patients with systemic lupus erythematosus. Saudi Med J. 2009, 30(10):1291-1295. PubMed PMID: 19838436.
32. Dayangac-Erden D., Karaduman A., Erdem-Yurter H. Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients. Arch. Dermatol. Res. 2007, 99:487-491.
33. Feser M., et al. Plasma 25,OH vitamin D concentrations are not associated with rheumatoid arthritis (RA)-related autoantibodies in individuals at elevated risk for RA. J. Rheumatol. 2009, 36:943-946.
34. Fraser W.D. Standardization of vitamin D assays: Art or science?. Ann. Clin. Biochem. 2009, 46:3-4.
35. Gaál J., Lakos G., Szodoray P., Kiss J., Horváth I., Horkay E., Nagy G., Szegedi A. Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: Results of an open, follow-up pilot study. Acta Derm. Venereol. 2009, 89:140-144.
36. Giovannucci E. Expanding roles of vitamin D. J. Clin. Endocrinol. Metab. 2009, 94:418-420.
37. Glendenning P., Taranto M., Noble J.M., et al. Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: Need for assay-specific decision limits and metabolite-specific assays. Ann. Clin. Biochem. 2006, 43:23-30.
38. Grant W.B. Epidemiology of disease risks in relation to vitamin D insufficiency. Prog. Biophys. Mol. Biol. 2006, 92:65-79.
39. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357:266-281.
40. Holick M.F. Vitamin D status: Measurement, interpretation, and clinical application. Ann. Epidemiol. 2009, 19:73-78.
41. Holick M.F. Vitamin D status: Measurement, interpretation, and clinical application. Ann. Epidemiol. 2009, 19:73-78.
42. Huckins D., Felson D.T., Holick M. Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: A pilot study. Arthritis Rheum. 1990, 33:1723-1727.
43. Huisman A.M., White K.P., Algra A., Harth M., Vieth R., Jacobs J.W.G., Bijlsma J.W.J., Bell D.A. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J. Rheumatol. 2001, 28:2535-2539.
44. Hypponen E., Laara E., Reunanen A., Jarvelin M.R., Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. Lancet 2001, 358:1500-1503.
45. Jesudason D., Need A.G., Horowitz M., O'Loughlin P.D., Morris H.A., Nordin B.E. Relationship between serum 25-hydroxyvitamin D and bone resorption markers in vitamin D insufficiency. Bone 2002, 31:626-630.
46. Jones G., Horst R., Carter G., Makin H.L.J. Contemporary diagnosis and treatment of vitamin D-related disorders. J. Bone Miner. Res. 2007, 22(S2):V11-V15.
47. Kamen D., Aranow C. Vitamin D in systemic lupus erythematosus. Curr. Opin. Rheumatol. 2008, 20:532-537.
48. Kamen D.L., Cooper G.S., Bouali H., Shaftman S.R., Hollis B.W., Gilkeson G.S. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun. Rev. 2006, 5:114-117.
49. Kim H.A., Sung J.M., Jeon J.Y., Yoon J.M., Suh C.H. Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus. Rheumatol Int 2010, [Epub ahead of print] PubMed PMID: 20352222.
50. Larsson P., et al. A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia. Clin. Exp. Immunol. 1998, 114:277-283.
51. Lemire J.M., et al. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity 1992, 12:143-148.
52. Linker-Israeli M., Elstner E., Klinenberg J.R., Wallace D.J., Koeffler H.P. Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin. Immunol. 2001, 99:82-93.
53. Linker-Israeli M., et al. Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin. Immunol. 2001, 99:82-93.
54. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocr. Rev. 2001, 22:477-501.
55. Littorin B., Blom P., Scholin A., Arnqvist H.J., Blohme G., Bolinder J., Ekbom-Schnell A., Eriksson J.W., Gudbjornsdottir S., Nystrom L., Ostman J., Sundkvist G. Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: Results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia 2006, 49:2847-2852.
56. Lyakh L.A., Sanford M., Chekol S., Young H.A., Roberts A.B. TGF-beta and vitamin D3 utilize distinct pathways to suppress IL-12 production and modulate rapid differentiation of human monocytes into CD83+ dendritic cells. J. Immunol. 2005, 15:2061-2070.
57. Ma Y., et al. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J. Clin. Invest. 2006, 116:892-904.
58. Malabanan A., Veronikis I.E., Holick M.F. Redefining vitamin D insufficiency. Lancet 1998, 351:805-806.
59. Mathieu C., Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol. Med. 2002, 8:174-179.
60. Merlino L.A., Curtis J., Mikuls T.R., et al. Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women's Health Study. Arthritis Rheum. 2004, 50:72-77.
61. Merlino L.A., et al. Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women's Health Study. Arthritis Rheum. 2004, 50:72-77.
62. Müller K., Kriegbaum N.J., Baslund B., Sorensen O.H., Thymann M., Bentzen K. Vitamin D3 metabolism in patients with rheumatic diseases: Low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin. Rheumatol. 1995, 14:397-400.
63. Nielen M.M., van Schaardenburg D., Lems W., et al. Vitamin D deficiency does not increase the risk of rheumatoid arthritis: Comment on the article by Merlino et al. Arthritis Rheum. 2006, 54:3719-3720.
64. Nielen M.M., et al. Vitamin D deficiency does not increase the risk of rheumatoid arthritis: Comment on the article by Merlino et al. Arthritis Rheum. 2006, 54:3719-3720.
65. O'Regan S., Chesney R.W., Hamstra A., Eisman J.A., O'Gorman A.M., Deluca H.F. Reduced serum 1,25-(OH)2 vitamin D3 levels in prednisone-treated adolescents with systemic lupus erythematosus. Acta Paediatr. Scand. 1979, 68:109-111.
66. Oelzner P., Muller A., Deschner F., et al. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif. Tissue Int. 1998, 62:193-198.
67. Orbach H., Zandman-Goddard G., Amital H., Barak V., Szekanecz Z., Szucs G., Danko K., Nagy E., Csepany T., Carvalho J.F., Doria A., Shoenfeld Y. Novel biomarkers in autoimmune diseases. Prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann. N. Y. Acad. Sci. 2007, 1109:385-400.
68. Patel S., et al. Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum. 2007, 56:2143-2149.
69. Penna G., Adorini L. 1Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 2000, 164:2405-2411.
70. Roth H.J., Schmidt-Gayk H., Weber H., Niederau C. Accuracy and clinical implications of seven 25-hydroxyvitamin D methods compared with liquid chromatography-tandem mass spectrometry as a reference. Ann. Clin. Biochem. 2008, 45:153-159.
71. Ruiz-Irastorza G., Egurbide M.V., Olivares N., Martinez-Berriotxoa A., Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: Prevalence, predictors and clinical consequences. Rheumatology 2008, 47:920-923.
72. Ruiz-Irastorza G., Gordo S., Olivares N., Egurbide M.V., Aguirre C. Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage. Arthritis Care Res. (Hoboken). 2010, 62(8):1160-1165. PubMed PMID: 20235208.
73. Sdeghi K., Wessner B., Laggner U., et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur. J. Immunol. 2006, 36:361-370.
74. Shapira Y., Agmon-Levin N., Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J. Autoimmun. 2010, 34:J168-J177.
75. Shoenfeld N., Amital H., Shoenfeld Y. The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease. Nat. Clin. Pract. Rheumatol. 2009, 5:99-105.
76. Sokka T. Rheumatoid arthritis data bases in Finland. Clin. Exp. Rheumatol. 2010, 23(Suppl. 39):S201-S204.
77. Stechschulte S.A., Kirsner R.S., Federman F.G. Vitamin D: Bone and beyond, rationale and recommendations for supplementation. Am. J. Med. 2009, 122:793-802.
78. Stockinger B. Th17 cells: An orphan with influence. Immunol. Cell Biol. 2007, 85:83-84.
79. Teichmann J., Lange U., Stracke H., Federlin K., Bretzel R.G. Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis. Rheumatol. Int. 1999, 18:137-140.
80. Tetlow L.C., Woolley D.E. The effects of 1 alpha,25-dihydroxyvitamin D(3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion. Arthritis Res. 1999, 1:63-70.
81. Thudi A., Yin S., Wandstrat A.E., Quan-Zhen L., Olsen N.J. Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. Am. J. Med. Sci. 2008, 335:99-104.
82. Toloza S.M.A., Cole D.E.C., Gladman D.D., Ibanez D., Urowitz M.B. Vitamin D insufficiency in a large female SLE cohort. Lupus 2010, 19:13-19.
83. van Etten E., Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts. J. Steroid Biochem. Mol. Biol. 2005, 97:93-101.
84. Vieth R., Ladak Y., Walfish P.G. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J. Clin. Endocrinol. Metab. 2003, 88:185-191.
85. Wright T.B., Shults J., Leonard M.B., Zemel B.S., Burnham J.M. Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J. Pediatr. 2009, 155:260-265.
86. Wu P.W., Rhew E.Y., Dyer A.R., Dunlop D.D., Langman C.B., Price H., Sutton-Tyrrel K., McPherson D.D., Edmundowicz D., Kondos G.T., Ramsey-Goldman R. 25-Hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Rheum. 2009, 61:1387-1395.
87. Xu H., Soruri A., Gieseler R.K., Peters J.H. 1,25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen. Scand. J. Immunol. 1993, 38:535-540.
88. Zold E., Szodoray P., Gaal J., Kappelmayer J., Csathy L., Gyimesi E., Zeher M., Szegedi G., Bodolay E. Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res. Ther. 2008, 10:R123.